Mutation Query
| | | | Allele 1: | G268A | | Allele 2: | G268A | Allelic information known | | Refine query |
|
| | | 268 |  |  |
| | Residue G268 | | Cluster assignment: | | | Cluster description: | Partitioning loop | | Subcluster: | 3A (residues 268-277) | | Subcluster description: | A region near the exo active site that comprises the Exo II motif | | POLG domain: | Exonuclease domain |
| Residue G268 | | Cluster assignment: | | | Cluster description: | Partitioning loop | | Subcluster: | 3A (residues 268-277) | | Subcluster description: | A region near the exo active site that comprises the Exo II motif | | POLG domain: | Exonuclease domain |
|
|
Mutation Information
|
| G268A | | | | Number of patients: (with G268A) | 2 | | Non-allelic with: | A467T (50%) G268A (50%) |  | Show Patient Data |
| Patient data are sorted by mutation combination frequency. | Reference: | Di Fonzo et al, 2003; | | Description: | PEO, age of onset 65 years. | | Mutations: | A467T, G268A | | Age group: | adult | | Age of Onset: 65, Age of Patient: n/a, Age of Death: n/a |
| Reference: | Del Bo et al, 2003; | | Description: | PEO, complicated by dysphagia, my- opathy, neuropathy pigmentary retinopathy and amenorrhea. | | Mutations: | G268A, G268A | | Age group: | adult | | Age of Onset: n/a, Age of Patient: 32, Age of Death: n/a |
|
|
|
|
|
The following information is based on existing patient data and pathogenic cluster assignment.
Pathogenicity information for a patient with mutations in Clusters 3 and 3: Age of onset information is extracted from a total of 21 patients and/ or patient families. | Age of onset | | |
21- 11- | 10
| 6
| 2
| 3
| | | infantile | childhd | juvenile | adult | | | 48% | 29% | 10% | 14% | |
All mutations mapping within the pathogenic clusters are at high risk for pathogenicity. In general, a patient must have a pathogenic mutation in both of his/ her POLG genes to develop a POLG-related syndrome. | Symptoms described in patients with cluster3-cluster3 mutations | |
| Symptoms in patients with combination
cluster3:cluster3 | | PEO | 42.9% | | Epilepsy | 33.3% | | Ptosis | 33.3% | | Encephalopathy | 33.3% | | Developmental delay | 33.3% | | Lactic acidosis | 23.8% | | Movement disorder (ataxia) | 19.0% | | Peripheral neuropathy | 19.0% | | Muscle weakness | 19.0% | | Ragged red fibers | 14.3% | | Exercise intolerance | 14.3% | | Dysphagia | 14.3% | | Myoclonic seizures | 9.5% | | Polyneuropathy | 9.5% | | Abnormal muscle histology | 9.5% | | Myopathy | 9.5% | | Liver failure | 9.5% | | Hypotonic | 9.5% | | Dementia | 9.5% | | CPK abnormalities | 9.5% | | +9 other symptoms in under 5.0% of the patients |
| | Data gathered from clinical descriptions for 21 patients |
| Symptoms by group | | CPEO | 52.4% | | Developmental Delay | 42.9% | | Myopathy | 42.9% | | Seizures | 38.1% | | Hepatopathy | 33.3% | | Neuropathy | 28.6% | | Alpers syndrome | 23.8% | | CNS symptoms | 23.8% | | Ataxia | 19.0% | | Hypotonia | 9.5% | | Other | 9.5% | | Unknown | 4.8% |
| | [Show grouping information] |
|
|
|
